Skip main navigation

Role of Exosomes in Myocardial Remodeling

Originally publishedhttps://doi.org/10.1161/CIRCRESAHA.114.300584Circulation Research. 2014;114:315–324

    Abstract

    Exosomes are nanovesicles released from cells through exocytosis and are known to be mediators of proximal as well as distant cell-to-cell signaling. They are surrounded by a classical bilayered membrane with an exceptionally high cholesterol/phospholipid ratio. Exosomes were first described in 1977, then named prostasomes, and in 1987 the name exosome was coined. Exosomes contain surface proteins, some of which can act as labels in order to find their target cells. Exosomes also contain messages in the form of proteins and nucleic acids (RNA and DNA) that are transferable to target cells. Little is known and written about cardiac exosomes, although Gupta and Knowlton described exosomes containing HSP60 in 2007. It is now known that exosomes from cardiomyocytes can transfect other cells and that the metabolic milieu of the parental cell decides the quality of exosomes released such that they induce differential gene expression in transfected cells. Future clinical use of exosomes in diagnosis, monitoring disease progress, and treatment is promising.

    Cardiac vascular disease (CVD) continues to be the most common cause of death, being 47% of all deaths according to European Cardiovascular Disease Statistics.1 In most Western countries, the CVD death rates are declining possibly because of progress in treatment strategies, such as valvular surgery, coronary bypass surgery, balloon dilatation of coronary vessels, β-blockers in acute myocardial infarction, as well as preventive initiatives, with smoking cessation being the most effective one. Earlier (particularly surgical) treatments have aimed to restore normal anatomy, whereas future therapies increasingly will be relying on cellular, subcellular, and molecular myocardial actions. A major step forward in molecular genetics in clinical cardiology took place with the finding by the Seidman group in 1989 that hypertrophic cardiomyopathy, in part, is due to a mutation in the myosin heavy chain gene.2 Since then, the ambition has been to look for a possible genetic basis in hitherto unexplained cardiac diseases as well as to explore new means of diagnosis and treatment based on modification of gene expression, microRNA (miR), and protein handling of the cell (synthesis, folding/chaperones, degradation by the ubiquitine–proteasome pathway). It has been reported that misfolding of proteins can lead to proteotoxicity, which is an important pathophysiologic mechanism in many heart diseases.3 Exosomes are vesicles released from cells via exocytosis, and myocardial exosomes may play a major role in many of the abovementioned processes. Although knowledge about specific myocardial exosome function and importance is limited, the subject is extensively studied at present. Analogous functions of cardiac exosomes are now looked for based on knowledge about exosomes from other cell systems.

    The first description of exosomes (prostasomes) was in epithelial glandular tissue.46 Glandular epithelial structures as well as unicellular systems were those initially thought to release exosomes.79 The first identification of exosomes in cancer-derived cells was made in prostate cancer cell lines PC3, Du145, and LnCaP grown in monolayer.10 This initial finding was followed by investigations on exosomes of other cancer cells.1114 Accordingly, subsequent investigations proved that most cells were able to produce exosomes.1521 Gupta and Knowlton22 reported in 2007 that cardiomyocytes grown in vitro could release exosomes and that they contained HSP60. Moreover, extracellular HSP60, when not in exosomes, may be apoptosis-inducing to the surrounding cardiac myocytes because of a probable activation of Toll-like receptor 4.23 Still, it is suggested that exosomes may be involved in mediating messages to proximal and distant cells for normal events such as cardiac development/growth, normal function, as well as pathology.

    Plasma Membrane

    Cardiac exosomes are derived from plasma membrane elements, and recognition of some properties of plasma membranes is important to understand extracellular vesicle formation (including exosomes) and behavior. About 100 years ago, Overton24 asserted that the barrier function of the plasma membrane could best be understood if it were attributed to lipids. Gorter and Grendel25 suggested a lipid double-layer structure and the idea was further explored by Davson and Danielli.26 They reasoned that the amphipathic nature of the phospholipid molecules and their conspicuous place as membrane components made them a dominant feature of the membrane. According to the model, the hydrocarbon sidechains were directed inwardly toward the center of the membrane, and the polar groups outwardly together with a layer of proteins made up the surfaces. In 1960, Robertson27 demonstrated the basic similarity of images of several membranes of a cell (ie, plasma membrane, nuclear membrane, and inner mitochondrial membrane) obtained by electron microscopy (unit membrane), in that many membranes of a cell are fundamentally similar in structure, consisting of a bilayer, 7 to 9 nm thick.

    The fluid model is another expression for the lipid bilayer model, with emphasis on the probable mobility of protein components in the lipid matrix. Singer and Nicolson28 introduced the concept of membrane surface proteins and transversing proteins, thus allowing some of the membrane proteins to move laterally on the cell surface. This was described as the fluid mosaic membrane. The phospholipid bilayer was no longer considered a continuum because of the presence of transversing proteins. Simons and Ikonen29 launched the raft hypothesis in 1997 describing a heterogeneous organization of the membrane (including lipid composition) with functional lipid raft microdomains, described in more detail elsewhere in this review.

    History of Exosomes

    In 1977, we described the extracellular presence of vesicles surrounded by a bilayer membrane in prostatic and seminal fluids.46 Electron microscopy examinations of acinar cells from surgically removed specimens of human prostatic tissue revealed that the extracellular vesicles, which we called prostasomes, corresponded to intracellular vesicles inside another larger vesicle, a so-called storage vesicle, equivalent to a multivesicular body (MVB)/multivesicular endosome of late endosomal origin.30 We also measured the diameter of prostasomes in 3 different locations: an intracellular location within storage vesicles, extracellularly in the acinar lumen, as well as (extracellularly) in isolated and purified prostasomes from prostatic and seminal fluids. We found similar mean values of ≈150 nm for all 3 locations. Moreover, the ultrastructure of the vesicles (prostasomes) was suggestive because, while inside the storage vesicles within the acinar cell, they could be released after fusion with the surrounding membrane of the storage vesicle and the plasma membrane of the acinar cell into the extracellular space, that is, exocytosis, into the glandular duct.30 Vesicles released in this way, thus, formally fulfill the criterion to be termed exosomes. Functional and beneficial effects of prostasomes on sperm cells were recognized early.31 Concomitantly, it was recognized that other cells could also be in receipt of these beneficial properties.32

    Electron microscopic studies by Pan et al7 in 1985 on maturing reticulocytes disclosed an intracellular sac filled with small membrane-enclosed structures nearly uniform in size. When these sacs fused with the plasma membrane, the vesicular contents were released,7 again an example of exocytosis. A similar finding was reported in 1984 by Harding et al8 for reticulocytes of another species. The Johnstone group9 interpreted this process to be something like reverse endocytosis, with internal vesicular contents released in contrast to external molecules internalized in membrane-bound structures, and in 1987, they named the extruded structures exosomes. The functionality of exosomes in case of reticulocytes was interpreted to represent shedding of some membrane proteins, which were known to diminish during the final stage of development to mature erythrocytes.33

    In 1996, Raposo et al34 demonstrated in B-lymphocytes that both the limiting membrane and the internal vesicles contain major histocompatibility complex class II, and the released exosomes were perceived to have a role in antigen presentation in vivo. Subsequently, it was realized that many cell types release exosomes, including hematopoietic cells, B- and T-lymphocytes, dendritic cells, mast cells, platelets, intestinal epithelial cells, astrocytes, neurons, and tumor cells.1521 In addition to exosomes, cells can also shed other types of extracellular membrane vesicles, namely, microvesicles, microparticles, and apoptotic bodies,35,36 after various biological stimuli, including induction of programmed cell death. Exosomes (especially those harvested from growth media of cells grown in vitro) have generally undergone a filtration step in their purification, and they, therefore, represent a population of membrane vesicles rather homogeneous in size (40–100 nm in diameter). Accordingly, regarding size, exosomes can be categorized into those with a narrow size range (because of filtration in the preparatory procedure) and those not filtered, with a broader size range (eg, prostasomes). In contrast, microvesicles, microparticles, and apoptotic bodies represent heterogeneous populations of extracellular vesicles (100 to >1000 nm) that are the result of a direct budding from the plasma membrane.

    Extracellular vesicles, including exosomes, have potent proinflammatory effects; they can affect the function of endothelium and promote coagulation. Therefore, they may play a role in the pathogenesis of CVDs. Hence, cancer cell– and endothelial cell–derived exosomes stimulate endothelial cells by receptor activation and transfer of exosomal effectors leading to the progression of angiogenesis in vitro and in vivo.3739 It should be kept in mind, however, that exosomes derived from mesenchymal stromal cells have been claimed to exert an anti-inflammatory effect on lung vessels. In this way, hypoxic pulmonary hypertension is inhibited via the suppression of macrophage action.40 This reasoning is relevant in revascularization of ischemic myocardium and justifies new approaches in trying to master exosome production and movement in interstitial fluid and peripheral blood.

    Exosome Biogenesis

    Better understanding of the biogenesis of exosomes has led to more insight during the past decades into their function.4144 Exosomes are a subgroup of extracellular vesicles generally ranging in size from 40 to 200 nm, which are released extracellularly through exocytosis.30,33,34 Interactions between cells, which are mediated by exosomes, lead to a much more complex event compared with those mediated by a single ligand with a single receptor. Most cells are capable of releasing exosomes. The plasma membrane of mammalian cells is organized heterogeneously, that is, there is no bilayer continuum. Instead, the bilayer is interrupted by so-called transversing proteins, which extend across the biological membrane. The plasma membrane also contains specific microdomains known as detergent-resistant membrane domains, lipid rafts, or caveolae.4548 More than 20 years ago, we observed an extraordinary composition of the membrane of prostasomes.49 The prostasomal membrane contains a high amount of saturated phospholipid acyl chains and sphingomyelin, which in turn results in an affinity for cholesterol. Hence, the cholesterol/phospholipid ratio was strikingly high (≈2, contrasting to most other biological membranes with a corresponding ratio of ≈0.8), and electron spin resonance studies revealed that lipids in the prostasome membrane were highly ordered.49 The implications of these findings were not clear at first but were explained some years later when Simons and Ikonen29 formulated the raft hypothesis. According to this hypothesis, sphingolipid–cholesterol microdomains are involved in numerous cellular functions, from membrane trafficking and cell morphogenesis to cell signaling. These rafts recruit a specific set of proteins and exclude others. The exact mechanisms of selection are not known. Endocytic vesicles arise at the lipid raft domain of the plasma membrane through clathrin- or nonclathrin-mediated endocytosis, leading to the intracellular formation of early endosomes. These early endosomes are subjected to a maturation process that includes an interaction with the Golgi complex to become late endosomes. The bilayer membrane surrounding late endosomes can in turn display invaginations, giving rise to intraluminal vesicles completing the formation of MVBs/multivesicular endosomes (or, in case of prostasome nomenclature, the so-called storage vesicles),30,50,51 rendering the membrane surrounding the intraluminal vesicles a right-side-out position in relation to the plasma membrane (Figure 1).52 The components of the endosomal sorting complex required for transport pathway are critical for the formation of MVBs (Figure 2). However, the relationship between the endosomal sorting complex required for transport pathway and the secretion of exosomes remains unclear. The fusion of MVBs with the plasma membrane results in the release of their cargo, the exosomes, to the extracellular space. This process completes the exocytosis event.

    Figure 1.

    Figure 1. Biogenesis of exosomes. Exosomes are generated in the late endosomal compartment and carry recycled proteins from coated pits/lipid rafts in the cellular membrane, proteins directly sorted to the MVBs from RER and GC, mRNA, microRNA, and DNA. Note that the generation of exosomes by inward budding of the limiting membrane of MVB ensures that the membrane-bound proteins preserve the same orientation and folding on the exosomal membrane as those on the plasma membrane. The exosome-filled MVBs are either fused with the plasma membrane to release exosomes or sent to lysosomes for degradation. Exosomes are different from ectosomes and apoptotic bodies because the latter extracellular vesicles are the result of a direct budding process of the plasma membrane. GC indicates Golgi complex; MV, microvesicle internalized from the cellular membrane, early endosomes; MVB, multivesicular body; and RER, rough endoplasmic reticulum. The role of placental exosomes in reproduction. (Illustration credit: Ben Smith). Reprinted from Mincheva-Nilsson and Baranov52 with permission of the publisher. Copyright © 2010 John Wiley & Sons A/S. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.

    Figure 2.

    Figure 2. Electron microscopy picture of a multivesicular body (MVB) containing intraluminal vesicles/exosomes. Note the surrounding double-layered membrane and intraluminal vesicles/exosomes of different sizes and densities. Image reprinted with permission from Dr Jastrow’s electron microscopic atlas (www.drjastrow.de).

    The protein composition of exosomes produced in vitro has been studied in various ways, including Western blotting,53,54 flow cytometry of exosome-coated beads,55 and mass spectrometry.5658 These studies have demonstrated that exosomes from different cellular origins share some common characteristics. Such characteristics are the lipid bilayer with exceptionally high cholesterol/phospholipid ratio, size, density, and a basic collection of lipid and protein composition. Among these proteins are those derived from the cytoplasm or some that are membrane-bound, such as tubulin, actin, actin-binding proteins, annexins and Rab proteins, and some glycolytic enzymes. Others represent those responsible for signal transduction, such as protein kinases and heterotrimeric G-proteins.5964 Many exosomes typically contain major histocompatibility complex class I and class II molecules65,66 and heat shock proteins62,67 that are involved in antigen binding and presentation. However, the protein family most characteristically associated with exosomes would seem to be the tetraspanin and integrin proteins (targeting and cell adhesion), including CD9, CD63, CD81, and CD826870 (Figure 3).

    Figure 3.

    Figure 3. Cartoon of an exosome. The exosomal contents comprise mRNA, DNA, microRNAs, proteins (ie, enzymes, growth factors, and cytokines), and transmembrane proteins of different kinds, including tetraspanins, annexin, and intracellular cell adhesion molecule. For further information, see text. Reprinted from Hu et al124 with permission of the publisher. Copyright © 2012, Frontiers in Genetics.

    Although differential centrifugations, including preparative ultracentrifugation, do not discriminate between exosomes and other small vesicles, or large protein aggregates, exosomes float on sucrose gradients, and their densities range from 1.13 g/mL (B-cell–derived exosomes) up to 1.19 g/mL (epithelial cell–derived exosomes). Accordingly, contaminating protein material can be separated from exosomes by floatation on sucrose gradient.67 Other modes of enrichment of prostasomes/exosomes include size exclusion chromatography14,30,31 filtration,56 immunoaffinity purification,71 and specific isolation kits.72

    The sorting behavior of lipids in MVBs/storage vesicles is not known. It has been claimed that it might be determined by the nature of their hydrophobic tails.73 We have noted the unusual distribution of phospholipids in prostasomes with sphingomyelin being predominant and with relatively high amounts of phosphatidylethanolamine and phosphatidylserine as well as with lysophospholipids, whereas phosphatidylcholine and especially phosphatidylinositol were found at consistently low levels.49 This prostasome/exosome-specific phospholipid pattern was subsequently confirmed by others.74,75 Exosomal lipids might be biologically active,57 and we reported in 1993 the presence of prostaglandin E in prostasomes.76 Exosomal prostaglandins have been shown to be able to trigger prostaglandin-dependent intracellular signaling pathways within the target cells.77 The local enrichment of prostaglandins in prostasomes/exosomes may favor a more efficient biological activity as compared with what can be achieved with prostaglandins in soluble form.78 This reasoning also holds true for other soluble molecules.

    Exosome–Target Cell Interaction

    Intercellular communication is essential for multicellular organisms to maintain vital functions. Direct cell-to-cell contact or transfer of secreted molecules can accomplish this communication. A third mode of contact between cells is the release of extracellular vesicles such as exosomes, with interaction and uptake by another cell. Using free-zone electrophoresis, we found that both prostasomes and spermatozoa (presumed target cells) had a net negative surface charge (prostasomes less negative than spermatozoa), favoring repulsive forces. Nevertheless, spermatozoa and prostasomes interacted strongly with each other, and the interaction site most probably had a hydrophobic character.79 This type of interaction enables prostasomes to act in close vicinity to spermatozoa. Not only prostasomes, but also other exosomes will certainly display net negative surface charges that facilitate the solubility and integrity of exosomes in body fluids such as blood plasma. The transfer of a message to distant cells could occur by 3 possible mechanisms: by direct contact between the exosomal membrane and the plasma membrane of the target cell, by fusion of the 2 membranes, or by target cell internalization of the exosome (Figure 4).80,81 By these means, a parental cell is able to communicate with a target cell in its vicinity or at a distance through an amplification process.

    Figure 4.

    Figure 4. Confocal image of a transfected fibroblast with exosomes derived from cardiomyocytes stained with acridin orange. Arrow shows DNA in the nucleus of fibroblasts. When switching to red wavelength, RNA was also envisaged (not shown in picture). Reprinted from Waldenström et al81 with permission of the publisher. Copyright © 2012, Waldenström et al.

    Cardiac Remodeling and Exosome Function

    Modern therapy of acute myocardial infarction has resulted in early increased survival, although heart failure due to loss of contracting myocardium is still a problem in survivors.82 The remaining myocardium has to adapt to meet the work requirement performed earlier by a larger myocardial mass.

    Many different stress factors can lead to heart failure. Most often, such stressors lead to events in the myocardium, including certain adaptive measures. When these adaptations are insufficient, a state of maladaptation occurs. Obvious adaptation is hypertrophy (increased wall thickness and decreased wall stress) concomitantly with change in cellular metabolism and contractility to increase cost-effectiveness (switch to the fetal gene program).83 The stress may be pressure-induced (hypertension, aortic stenosis), volume-induced/increased blood flow (valve insufficiency), or induced by the loss of contractile myocardium (myocardial infarction or dilated cardiomyopathy). The heart strives for the maintenance of adequate cardiac output, that is, through increased sympathetic tone, which in the short term is adaptive, but in the long term is deleterious. The adaptive measures are orchestrated by different signal substances, such as chemokines, growth factors, miRs, many of which are mediated via exosomes from cardiac cells.

    In 1998, Fire et al84 described short, ≈19 to 23 nucleotides, noncoding ribonucleic acid molecules (miRs) that play important gene regulatory roles. They bind to complementary sequences on target mRNA, causing translational repression or target degradation and gene silencing.85 Several cellular processes such as proliferation, differentiation, and apoptosis are regulated by miRs.86 Recent studies revealed that miRs are aberrantly expressed in the cardiovascular system under some pathological conditions. Hence, complex changes in miRs occur during prolonged CVDs, such as cardiac hypertrophy.8789 Myocardial miRs are downregulated in the early stage of hypertrophy. miR-21 reaches 8 times upregulation by day 14 of induction of experimental cardiac hypertrophy and regulates apoptotic mechanisms. Also, miR-23 has a similar pattern of expression and function.90,91 miR-21 and miR-26a also regulate the expression of matrix metalloproteinase (MMP)-2, known to be important in extracellular matrix remodeling during hypertrophy.92,93 miR-26 and miR-133a/b are highly expressed in muscle and heart, but are only expressed in late-stage hypertrophy. miR-133 regulates the IP3 channel receptor gene, leading to prohypertrophic calcium signaling. miR-499 is embedded in the myosin heavy chain gene and is important in its regulation during hypertrophy.94 miR-30b-5p is downregulated in cardiac hypertrophy and regulates Ca2+/calmodulin-dependent protein kinase A. Such complex changes in miRs discussed for long-standing CVDs are also valid during acute events such as myocardial infarction.95,96

    Signaling between endothelial cells, endothelial progenitor cells, and stromal cells is crucial for the establishment and maintenance of vascular integrity and involves exosomes, among other signaling pathways. van Balkom et al97 showed that miR-214 (a miR that controls endothelial cell function and angiogenesis) plays a dominant role in exosome-mediated signaling between endothelial cells. Endothelial cell–derived exosomes turned out to stimulate migration and angiogenesis in target cells, whereas exosomes from miR-214–depleted endothelial cells failed to stimulate these processes. Results from another research group98 revealed that atheroprotective stimuli induced communication between endothelial cells and smooth muscle cells through a miR- and extracellular vesicle–mediated mechanism, suggesting a promising strategy to combat atherosclerosis. Another possible antiatherosclerotic exosome-mediated mechanism is already commented upon.40

    Although subjected to debate, a recent investigation established that the majority of miRs in blood plasma (and saliva) are enclosed in exosomes.99 Few years ago, Ji et al100 applied an analogous experimental approach to identify circulating miRs that might accurately reflect myocardial injury in vivo. Accordingly, miRs apparently circulate in an exosome-shielded form in body fluids such as blood plasma, and this established a basis for the idea that circulating miRs could serve as a new generation of biomarkers for CVDs.101104

    With the rapid expansion in stem cell research (including cardiosphere-derived stem cells), hope arose that stem cells could be seeded in myocardial cell–deficient tissue. Despite great efforts with seeding of different types of stem cells, this has not led to the expected positive result. Moreover, it was observed that despite a measurable increase in cardiac function, this could not be attributed to an abundance of stem cell invasion alone. Another explanation was that a paracrine function of stem cells and other cells could induce remodeling and cell protection, as well as improved function and facilitate cell transformation to cardiomyocytes.105108 Recent findings suggest that a surprisingly high number of different miRs can independently trigger cardiomyocyte mitosis in the border zone of an infarction, emphasizing the superiority of exosomal miRs over stem cell implantation in restitution of infarcted myocardium. This opens up for a new treatment strategy replacing stem cell implantation.109

    The paracrine functional capacity of cardiac exosomes has been shown indirectly by our group as well as by others. Cardiac cells can release exosomes that contain heat shock proteins, among others, and nucleic acids.22,81,110 The population of such cardiomyocyte-derived exosomes is not homogeneous. They differ in size from 40 to 300 nm, and some are electron-lucent, and others electron-dense.81 When characterized by surface proteins, 80% contain flotillin-1 and 30% are positive for caveolin-3. Moreover, exosomes released from cultured HL-1 murine cardiomyocytes contained 1595 different mRNAs, of which 1520 also were detected in cardiomyocytes and 423 could be directly connected to a biological network.81,111 Accordingly, 35 genes coding for proteins in the small and large ribosomal subunit and additional 8 genes could be connected to a network. Finally, 33 genes coded for proteins in the mitochondria. These exosomes were internalized by fibroblasts when cocultivated, and it could be demonstrated that exosomes were forwarded to the nucleus where both exosomal DNA and RNA colocalized. Exosomes were functional in that they induced a gene response of the transfected cells, giving rise to 333 differentially expressed genes (175 upregulations and 158 downregulations) compared with controls. Moreover, 343 different chromosomal DNA sequences were identified. The question arises whether these unequivocal effects are applicable to other cardiomyocyte cell lines. This relevant question cannot be answered until proper comparisons are made.

    It is notable that the milieu of the parental cell may influence the quality of exosomes released. Thus, when HL-1 cells were cultured with different growth factors, namely, transforming growth factor (TGF)-β2 or platelet-derived growth factor BB, individual responses were induced concerning the quality of exosomes released. Exosomes were isolated from each group of the treated cardiomyocytes and were cocultivated with fibroblasts. In the 3 groups of transfected fibroblasts (with exosomes derived from cells treated with TGF-β2, or platelet-derived growth factor BB, or controls), a common pool of 235 transcripts was found in all 3 groups where 14% were ribosomal and 5% were connected to the energy supply system. Apart from this, there were 138 transcripts unique for controls. Cardiomyocyte-derived exosomes contain a basic stock of transcripts common for exosomes derived from controls as well as growth factor–stimulated myocytes. The products are involved in intracellular transport, mitogen-activated protein kinase signaling pathways, and the nucleus. TGF-β2–derived exosomes induced 201 platelet-derived growth factor BB 74–specific transcripts, apart from the 138 in untreated controls.110 It may be concluded that cardiomyocyte-derived exosomes carry a basic package of transcripts and growth factor stimulators of cardiomyocytes, resulting in the alteration of the transcriptional content in a specific way. Thus, the conditions under which the parental cell maintains life is decisive for the quality of the exosomal message sent by the cell. It is of fundamental interest to know that cardiomyocytes can send messages with specific content according to the need or will of the sending cell. Examples of this are outlined below when the myocardium adapts to the external stimuli (such as different forms of stress), inducing hypertrophy and changes in contractility. Such adaptation to increased workload (valvular disease, hypertension, loss of myocardium/infarction) can generally be described as remodeling.

    Literature on cardiac exosomes is limited, but certain assumptions can be made based on the knowledge about exosomes from other tissues. Remodeling of the heart involves interplay mainly between cardiac cells, myocytes, fibroblasts, endothelial cells, smooth muscle cells, and extracellular matrix (and inflammatory cells). In particular, myocyte–fibroblast interaction is of importance.112 This interplay enables myocardial cells to grow or proliferate or be substituted by stem cells/fibroblasts transformed into cardiomyocytes. This includes angioneogenesis for regeneration of scarred myocardium or poorly perfused myocardium.109 This complicated and only partly known interplay is to some extent governed by signals delivered by exosomes.

    In 2008, a series of important articles from Utrecht demonstrated that a mesenchymal stem cell–conditioned medium, when given intravenously just before reperfusion after ischemia, induced limited infarct size in both pigs and mice.113 Injection of isolated exosomes into a tail vein before reperfusion of coronary ligated mice resulted in limitation of myocardial infarct size.114 This article also suggests an explanation for the paracrine effect of mesenchymal stem cell implantation on tissue repair. Moreover, it was shown that exosomes derived from cardiomyocyte progenitor cells stimulate the migration of endothelial cells. Human cardiomyocyte progenitor cells were cultivated, and exosomes were isolated from the medium. A major factor for endothelial cell migration was the exosomal contents of MMPs. A membrane-bound MMP activator is also found in these exosomes, which induces MMP and vascular endothelial growth factor release from neighboring cells.115 Progenitor cell–derived medium, including exosomes, modulates cell differentiation, proliferation, and survival of cardiac progenitor cells, cardiomyocytes, and fibroblasts.116119 It was reported recently that when the mechanism of protection was further studied in this mouse ischemia reperfusion model, ventricular dilatation was prevented and myocardial function improved. It was suggested that exosomes activated the survival pathways and restored ATP depletion. These exosomes also carry CD73 (5′-nucleotidase) that can produce extracellular adenosine, a well-known mediator of protection in ischemic preconditioning.120122 Finally, the inflammatory reaction to ischemia was shown to be reduced.123 It is still not known which exosomal factors are most important for the effects described above, but this body of results so far supports the interpretation that certain growth factors and cytokines, such as basic fibroblast growth factor, tumor necrosis factor-α, TGF-β, epidermal growth factor, heat shock proteins (HSP20, 60, and 70), and miRs known to be carried by exosomes, are, at least in part, responsible for the response.110,124,125128

    Ischemic preconditioning was first described by Murry et al129 in 1986. Several factors have been shown to function in this phenomenon, including adenosine, ATP-dependent K+ channels, mitochondrial transition pores, and some other factors.130132 It was recently found that this complex system is also governed by factors that are known to be exosome-borne, much the same way as in ischemia/reperfusion injury described above. They are likely to be important especially in the late phase of preconditioning, as first described by Bolli.133 Similarly, miRs that are involved in ischemic injury and preconditioning and known to be carried by exosomes include miR-1 (post-transcriptional regulation of HSP60 and 70), miR-21 (control of cell survival and expression of MMPs), miR-29 (regulates p53 and induces apoptosis), miR-133a (regulates hypertrophy and apoptosis), and miR-499 (inhibits apoptosis).134138 MMPs (regulated by miRs) induce degradation of scar tissue and substitution by invading transformed cells.115 Dying or apoptotic cells convey emergency signals, and rescue packages are sent back from stem cells, which to a certain extent are mediated via exosomes.124

    Exosomes with their narrow spectrum of molecules (nucleic acids, proteins, and lipids) may well be mediators of all these processes, thereby modulating cellular responses and signal transduction.57 It should be kept in mind that protein and RNA sorting into exosomes is highly regulated,139 and this allows cells to produce tailormade exosomes with different functional characteristics, in turn governed by the nature of signals triggering their production and release. After release, exosomes are targeted specifically to conjugated and distant cells as well. Accordingly, exosome release and cellular uptake are tightly controlled, and if we are able to govern this release and understand the mechanisms involved, we might be able to control the process.

    Future Aspects

    The era of clinical use of exosomes is just beginning. With the increased rate of publications, it can be expected that the field of use will also develop into unexpected areas.

    Exosomes in peripheral blood most probably reflect the status of the whole organ of exosomal origin and can, therefore, be expected to be used for:

    • Diagnosis, for example, acute myocardial infarction

    • Screening, for example, silent ischemia and hypertrophic cardiomyopathy

    • Prognosis, for example, myocardial infarction

    • Monitoring disease progression; exosome number and quality would reflect progression

    • Monitoring treatment efficacy, for example, normalization of exosome number and quality

    • Treatment, for example, as vehicle for gene therapy

    Because the status of the parental cell decides the quality of exosomes released, it is assumed that exosomes can be used to diagnose organ disease. The methods for diagnosis and prognostication of prostate cancer are under development.140 This method will have advantages over biopsies because exosomes reflect the whole part of sick tissue, whereas biopsies might miss the diseased part. The quality and quantity of exosomes might tell severity of the disease as, for example, in cancer but also in congestive heart failure and hypertrophic cardiomyopathy depending on which miR, mRNA, and DNA are found.110 Moreover, the treatment effect could be monitored by these means. Many monogenic diseases do not start at a given time, for example, the onset of hypertrophic cardiomyopathy ranges from childhood to adulthood. The monitoring of the quality of circulating exosomes might give a hint of when to start therapy like β-blockers or implantable cardioverter defibrillator, and they will also be excellent for screening purposes. Finally, exosomes loaded with therapeutic contents (DNA, RNA, and miRs) will probably be possible to generate in the future.

    This Review is part of a thematic series on Exosomes in Cardiovascular Disease, which includes the following articles:

    Role of Exosomes in Myocardial Remodeling

    Exosomes: Nanoparticles Involved in Cardioprotection?

    Exosomes and Cardiac Repair After Myocardial Infarction

    Microvesicles as Cell–Cell Messengers in Cardiovascular Diseases

    Ali J. Marian, Editor

    Nonstandard Abbreviations and Acronyms

    CVD

    cardiovascular disease

    miR

    microRNA

    MMP

    matrix metalloproteinase

    MVB

    multivesicular body

    TGF

    transforming growth factor

    Acknowledgments

    Professors Michael Haney and Joe Hayes are greatly appreciated for their careful reading and linguistic improvement of the article.

    Footnotes

    In November 2013, the average time from submission to first decision for all original research papers submitted to Circulation Research was 14.6 days.

    The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.114.300584/-/DC1.

    Correspondence to Anders Waldenström, MD, Department of Cardiology, Heart Centre, and Department of Public Health and Clinical Medicine, Umeå University, 90185 Umeå, Sweden. E-mail

    References

    • 1. Nichols M, Townsend N, Longo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner R. European Cardiovascular Disease Statistics 2012. Sophia Antipolis, France:European Heart Network, European Society of Cardiology;2012:8Google Scholar
    • 2. Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, Donis-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1.N Engl J Med. 1989; 321:1372–1378.CrossrefMedlineGoogle Scholar
    • 3. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction–Alzheimer’s disease of the heart?N Engl J Med. 2013; 368:455–464.CrossrefMedlineGoogle Scholar
    • 4. Ronquist G, Hedström M. Restoration of detergent-inactivated adenosine triphosphatase activity of human prostatic fluid with concanavalin A.Biochim Biophys Acta. 1977; 483:483–486.CrossrefMedlineGoogle Scholar
    • 5. Ronquist G, Brody I, Gottfries A, Stegmayr B. An Mg2+ and Ca2+-stimulated adenosine triphosphatase in human prostatic fluid: part I.Andrologia. 1978; 10:261–272.CrossrefMedlineGoogle Scholar
    • 6. Ronquist G, Brody I, Gottfries A, Stegmayr B. An Mg2+ and Ca2+-stimulated adenosine triphosphatase in human prostatic fluid–part II.Andrologia. 1978; 10:427–433.CrossrefMedlineGoogle Scholar
    • 7. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes.J Cell Biol. 1985; 101:942–948.CrossrefMedlineGoogle Scholar
    • 8. Harding C, Heuser J, Stahl P. Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding.Eur J Cell Biol. 1984; 35:256–263.MedlineGoogle Scholar
    • 9. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes).J Biol Chem. 1987; 262:9412–9420.CrossrefMedlineGoogle Scholar
    • 10. Nilsson BO, Lennartsson L, Carlsson L, Nilsson S, Ronquist G. Expression of prostasome-like granules by the prostate cancer cell lines PC3, Du145 and LnCaP grown in monolayer.Ups J Med Sci. 1999; 104:199–206.CrossrefMedlineGoogle Scholar
    • 11. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L. Malignant effusions and immunogenic tumour-derived exosomes.Lancet. 2002; 360:295–305.CrossrefMedlineGoogle Scholar
    • 12. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, van Meerbeeck JP, Burgers SA, Hoogsteden HC, Lambrecht BN. Proteomic analysis of exosomes isolated from human malignant pleural effusions.Am J Respir Cell Mol Biol. 2004; 31:114–121.CrossrefMedlineGoogle Scholar
    • 13. Mears R, Craven RA, Hanrahan S, Totty N, Upton C, Young SL, Patel P, Selby PJ, Banks RE. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry.Proteomics. 2004; 4:4019–4031.CrossrefMedlineGoogle Scholar
    • 14. Taylor DD, Gerçel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects.Br J Cancer. 2005; 92:305–311.CrossrefMedlineGoogle Scholar
    • 15. Zitvogel L, Angevin E, Tursz T. Dendritic cell-based immunotherapy of cancer.Ann Oncol. 2000; 11(suppl 3):199–205.CrossrefMedlineGoogle Scholar
    • 16. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z. Induction of heat shock proteins in B-cell exosomes.J Cell Sci. 2005; 118:3631–3638.CrossrefMedlineGoogle Scholar
    • 17. Skokos D, Goubran-Botros H, Roa M, Mécheri S. Immunoregulatory properties of mast cell-derived exosomes.Mol Immunol. 2002; 38:1359–1362.CrossrefMedlineGoogle Scholar
    • 18. Amigorena S. Anti-tumour immunotherapy using dendritic-cell-derived exosomes.Res Immunol. 1998; 149:661–662.CrossrefMedlineGoogle Scholar
    • 19. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.Blood. 1999; 94:3791–3799.CrossrefMedlineGoogle Scholar
    • 20. van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N, Heyman M. Intestinal epithelial cells secrete exosome-like vesicles.Gastroenterology. 2001; 121:337–349.CrossrefMedlineGoogle Scholar
    • 21. Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R. Exosomes are released by cultured cortical neurones.Mol Cell Neurosci. 2006; 31:642–648.CrossrefMedlineGoogle Scholar
    • 22. Gupta S, Knowlton AA. HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway.Am J Physiol Heart Circ Physiol. 2007; 292:H3052–H3056.CrossrefMedlineGoogle Scholar
    • 23. Malik ZA, Kott KS, Poe AJ, Kuo T, Chen L, Ferrara KW, Knowlton AA. Cardiac myocyte exosomes: stability, HSP60, and proteomics.Am J Physiol Heart Circ Physiol. 2013; 304:H954–H965.CrossrefMedlineGoogle Scholar
    • 24. Overton E. The probable origin and physiological significance of cellular osmotic properties.Vierteljahrschrift der Naturforschende Gesselschaft. 1899; 44:88–135.Google Scholar
    • 25. Gorter E, Grendel F. On bimolecular layers of lipoids on the chromocytes of the blood.J Exp Med. 1925; 41:439–443.CrossrefMedlineGoogle Scholar
    • 26. Davson H, Danielli JF. Studies on the permeability of erythrocytes: factors in cation permeability.Biochem J. 1938; 32:991–1001.CrossrefMedlineGoogle Scholar
    • 27. Robertson JD. The molecular structure and contact relationships of cell membranes.Prog Biophys Mol Biol. 1960; 10:343–418.MedlineGoogle Scholar
    • 28. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes.Science. 1972; 175:720–731.CrossrefMedlineGoogle Scholar
    • 29. Simons K, Ikonen E. Functional rafts in cell membranes.Nature. 1997; 387:569–572.CrossrefMedlineGoogle Scholar
    • 30. Ronquist G, Brody I. The prostasome: its secretion and function in man.Biochim Biophys Acta. 1985; 822:203–218.CrossrefMedlineGoogle Scholar
    • 31. Stegmayr B, Ronquist G. Promotive effect on human sperm progressive motility by prostasomes.Urol Res. 1982; 10:253–257.CrossrefMedlineGoogle Scholar
    • 32. Babiker AA, Ronquist G, Nilsson UR, Nilsson B. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement- mediated hemolysis.Am J Reprod Immunol. 2002; 47:183–192.CrossrefMedlineGoogle Scholar
    • 33. Johnstone RM. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins.Biochem Cell Biol. 1992; 70:179–190.CrossrefMedlineGoogle Scholar
    • 34. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles.J Exp Med. 1996; 183:1161–1172.CrossrefMedlineGoogle Scholar
    • 35. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death.Am J Pathol. 1995; 146:3–15.MedlineGoogle Scholar
    • 36. Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, Freyssinet JM. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection.J Clin Invest. 1997; 99:1546–1554.CrossrefMedlineGoogle Scholar
    • 37. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin.Cancer Res. 2002; 62:6312–6317.MedlineGoogle Scholar
    • 38. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.Blood. 2007; 110:2440–2448.CrossrefMedlineGoogle Scholar
    • 39. Hong BS, Cho JH, Kim H, Choi EJ, Rho S, Kim J, Kim JH, Choi DS, Kim YK, Hwang D, Gho YS. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells.BMC Genomics. 2009; 10:556.CrossrefMedlineGoogle Scholar
    • 40. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, Sdrimas K, Fernandez-Gonzalez A, Kourembanas S. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.Circulation. 2012; 126:2601–2611.LinkGoogle Scholar
    • 41. Ronquist G. Prostasomes are mediators of intercellular communication: from basic research to clinical implications.J Intern Med. 2012; 271:400–413.CrossrefMedlineGoogle Scholar
    • 42. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses.Nat Rev Immunol. 2009; 9:581–593.CrossrefMedlineGoogle Scholar
    • 43. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more.Trends Cell Biol. 2009; 19:43–51.CrossrefMedlineGoogle Scholar
    • 44. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication.Kidney Int. 2010; 78:838–848.CrossrefMedlineGoogle Scholar
    • 45. Anderson RG. The caveolae membrane system.Annu Rev Biochem. 1998; 67:199–225.CrossrefMedlineGoogle Scholar
    • 46. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts.J Biol Chem. 2000; 275:17221–17224.CrossrefMedlineGoogle Scholar
    • 47. Keller P, Simons K. Post-Golgi biosynthetic trafficking.J Cell Sci. 1997; 110(Pt 24):3001–3009.CrossrefMedlineGoogle Scholar
    • 48. Simons K, Toomre D. Lipid rafts and signal transduction.Nat Rev Mol Cell Biol. 2000; 1:31–39.CrossrefMedlineGoogle Scholar
    • 49. Arvidson G, Ronquist G, Wikander G, Ojteg AC. Human prostasome membranes exhibit very high cholesterol/phospholipid ratios yielding high molecular ordering.Biochim Biophys Acta. 1989; 984:167–173.CrossrefMedlineGoogle Scholar
    • 50. Sahlén GE, Egevad L, Ahlander A, Norlén BJ, Ronquist G, Nilsson BO. Ultrastructure of the secretion of prostasomes from benign and malignant epithelial cells in the prostate.Prostate. 2002; 53:192–199.CrossrefMedlineGoogle Scholar
    • 51. Février B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages.Curr Opin Cell Biol. 2004; 16:415–421.CrossrefMedlineGoogle Scholar
    • 52. Mincheva-Nilsson L, Baranov V. The role of placental exosomes in reproduction.Am J Reprod Immunol. 2010; 63:520–533.CrossrefMedlineGoogle Scholar
    • 53. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.Nat Med. 1998; 4:594–600.CrossrefMedlineGoogle Scholar
    • 54. Schrimpf SP, Hellman U, Carlsson L, Larsson A, Ronquist G, Nilsson BO. Identification of dipeptidyl peptidase IV as the antigen of a monoclonal anti-prostasome antibody.Prostate. 1999; 38:35–39.CrossrefMedlineGoogle Scholar
    • 55. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry.J Immunol Methods. 2001; 247:163–174.CrossrefMedlineGoogle Scholar
    • 56. Théry C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73.J Cell Biol. 1999; 147:599–610.CrossrefMedlineGoogle Scholar
    • 57. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Möbius W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation.J Biol Chem. 2003; 278:10963–10972.CrossrefMedlineGoogle Scholar
    • 58. Poliakov A, Spilman M, Dokland T, Amling CL, Mobley JA. Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen.Prostate. 2009; 69:159–167.CrossrefMedlineGoogle Scholar
    • 59. Stegmayr B, Brody I, Ronquist G. A biochemical and ultrastructural study on the endogenous protein kinase activity of secretory granule membranes of prostatic origin in human seminal plasma.J Ultrastruct Res. 1982; 78:206–214.CrossrefMedlineGoogle Scholar
    • 60. Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line.J Cell Sci. 2004; 117:5343–5351.CrossrefMedlineGoogle Scholar
    • 61. de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes.Blood. 2003; 102:4336–4344.CrossrefMedlineGoogle Scholar
    • 62. Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles.J Immunol. 2001; 166:7309–7318.CrossrefMedlineGoogle Scholar
    • 63. Mathivanan S, Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA.Proteomics. 2009; 9:4997–5000.CrossrefMedlineGoogle Scholar
    • 64. Ronquist KG, Ek B, Stavreus-Evers A, Larsson A, Ronquist G. Human prostasomes express glycolytic enzymes with capacity for ATP production.Am J Physiol Endocrinol Metab. 2013; 304:E576–E582.CrossrefMedlineGoogle Scholar
    • 65. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex.J Immunol. 2002; 168:3235–3241.CrossrefMedlineGoogle Scholar
    • 66. Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.Nat Med. 2001; 7:297–303.CrossrefMedlineGoogle Scholar
    • 67. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function.Nat Rev Immunol. 2002; 2:569–579.CrossrefMedlineGoogle Scholar
    • 68. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes.J Biol Chem. 1998; 273:20121–20127.CrossrefMedlineGoogle Scholar
    • 69. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, van Meerbeeck JP, Burgers SA, Hoogsteden HC, Lambrecht BN. Proteomic analysis of exosomes isolated from human malignant pleural effusions.Am J Respir Cell Mol Biol. 2004; 31:114–121.CrossrefMedlineGoogle Scholar
    • 70. Chaput N, Taïeb J, André F, Zitvogel L. The potential of exosomes in immunotherapy.Expert Opin Biol Ther. 2005; 5:737–747.CrossrefMedlineGoogle Scholar
    • 71. Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, Simpson RJ. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature.Mol Cell Proteomics. 2010; 9:197–208.CrossrefMedlineGoogle Scholar
    • 72. Taylor DD, Zacharias W, Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling.Methods Mol Biol. 2011; 728:235–246.CrossrefMedlineGoogle Scholar
    • 73. Mukherjee S, Soe TT, Maxfield FR. Endocytic sorting of lipid analogues differing solely in the chemistry of their hydrophobic tails.J Cell Biol. 1999; 144:1271–1284.CrossrefMedlineGoogle Scholar
    • 74. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes.Traffic. 2002; 3:321–330.CrossrefMedlineGoogle Scholar
    • 75. Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux JF, Kobayashi T, Salles JP, Perret B, Bonnerot C, Record M. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization.Biochem J. 2004; 380:161–171.CrossrefMedlineGoogle Scholar
    • 76. Oliw EH, Fabiani R, Johansson L, Ronquist G. Arachidonic acid 15-lipoxygenase and traces of E prostaglandins in purified human prostasomes.J Reprod Fertil. 1993; 99:195–199.CrossrefMedlineGoogle Scholar
    • 77. Subra C, Grand D, Laulagnier K, Stella A, Lambeau G, Paillasse M, De Medina P, Monsarrat B, Perret B, Silvente-Poirot S, Poirot M, Record M. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins.J Lipid Res. 2010; 51:2105–2120.CrossrefMedlineGoogle Scholar
    • 78. Lee HM, Choi EJ, Kim JH, Kim TD, Kim YK, Kang C, Gho YS. A membranous form of ICAM-1 on exosomes efficiently blocks leukocyte adhesion to activated endothelial cells.Biochem Biophys Res Commun. 2010; 397:251–256.CrossrefMedlineGoogle Scholar
    • 79. Ronquist G, Nilsson BO, Hjertën S. Interaction between prostasomes and spermatozoa from human semen.Arch Androl. 1990; 24:147–157.CrossrefMedlineGoogle Scholar
    • 80. Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy.J Cell Biochem. 2010; 111:488–496.CrossrefMedlineGoogle Scholar
    • 81. Waldenström A, Gennebäck N, Hellman U, Ronquist G. Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells.PLoS One. 2012; 7:e34653.CrossrefMedlineGoogle Scholar
    • 82. Jhund PS, McMurray JJ. Heart failure after acute myocardial infarction: a lost battle in the war on heart failure?Circulation. 2008; 118:2019–2021.LinkGoogle Scholar
    • 83. Waldenström A, Schwartz K, Swynghedauw B. Cardiac hypertrophy: from fetal to fatal?Clin Physiol. 1989; 9:315–320.CrossrefMedlineGoogle Scholar
    • 84. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature. 1998; 391:806–811.CrossrefMedlineGoogle Scholar
    • 85. Carrington JC, Ambros V. Role of microRNAs in plant and animal development.Science. 2003; 301:336–338.CrossrefMedlineGoogle Scholar
    • 86. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function.Cell. 2004; 116:281–297.CrossrefMedlineGoogle Scholar
    • 87. Chen J, Huang ZP, Seok H, Ding J, Kataoka M, Zhang Z, Hu X, Wang G, Lin Z, Wang S, Pu W, Liao R, Wang DZ. Mir-17–92 cluster is required for and sufficient to induce cardiomyocyte proliferation in Postnatal and adult hearts.Circ Res. 2013; 112:1557–1566.LinkGoogle Scholar
    • 88. Huang ZP, Chen J, Seok HY, Zhang Z, Kataoka M, Hu X, Wang DZ. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress.Circ Res. 2013; 112:1234–1243.LinkGoogle Scholar
    • 89. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M. Functional screening identifies miRNAs inducing cardiac regeneration.Nature. 2012; 492:376–381.CrossrefMedlineGoogle Scholar
    • 90. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy.Circ Res. 2007; 100:416–424.LinkGoogle Scholar
    • 91. Busk PK, Cirera S. MicroRNA profiling in early hypertrophic growth of the left ventricle in rats.Biochem Biophys Res Commun. 2010; 396:989–993.CrossrefMedlineGoogle Scholar
    • 92. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ, Sen CK. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue.Cardiovasc Res. 2009; 82:21–29.CrossrefMedlineGoogle Scholar
    • 93. Wei C, Kim IK, Kumar S, Jayasinghe S, Hong N, Catalucci D, Castoldi G, Jones WK, Gupta S. NF-κB mediated miR-26a regulation in cardiac fibrosis.J Cell Physiol. 2013; 228:1433–1442.CrossrefMedlineGoogle Scholar
    • 94. Shieh JT, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response.PLoS One. 2011; 6:e19481.CrossrefMedlineGoogle Scholar
    • 95. Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function.Nature. 2013; 495:107–110.CrossrefMedlineGoogle Scholar
    • 96. Fiedler J, Thum T. MicroRNAs in myocardial infarction.Arterioscler Thromb Vasc Biol. 2013; 33:201–205.LinkGoogle Scholar
    • 97. van Balkom BW, de Jong OG, Smits M, Brummelman J, den Ouden K, de Bree PM, van Eijndhoven MA, Pegtel DM, Stoorvogel W, Würdinger T, Verhaar MC. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells.Blood. 2013; 121:3997–4006, S1.CrossrefMedlineGoogle Scholar
    • 98. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs.Nat Cell Biol. 2012; 14:249–256.CrossrefMedlineGoogle Scholar
    • 99. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes.PLoS One. 2012; 7:e30679.CrossrefMedlineGoogle Scholar
    • 100. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury.Clin Chem. 2009; 55:1944–1949.CrossrefMedlineGoogle Scholar
    • 101. van Empel VP, De Windt LJ, da Costa Martins PA. Circulating miRNAs: reflecting or affecting cardiovascular disease?Curr Hypertens Rep. 2012; 14:498–509.CrossrefMedlineGoogle Scholar
    • 102. Eitel I, Adams V, Dieterich P, Fuernau G, de Waha S, Desch S, Schuler G, Thiele H. Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction.Am Heart J. 2012; 164:706–714.CrossrefMedlineGoogle Scholar
    • 103. Gidlöf O, Smith JG, Miyazu K, Gilje P, Spencer A, Blomquist S, Erlinge D. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction.BMC Cardiovasc Disord. 2013; 13:12.CrossrefMedlineGoogle Scholar
    • 104. Pleister A, Selemon H, Elton SM, Elton TS. Circulating miRNAs: novel biomarkers of acute coronary syndrome?Biomark Med. 2013; 7:287–305.CrossrefMedlineGoogle Scholar
    • 105. Doroudgar S, Glembotski CC. The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart.Trends Mol Med. 2011; 17:207–214.CrossrefMedlineGoogle Scholar
    • 106. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.Lancet. 2012; 379:895–904.CrossrefMedlineGoogle Scholar
    • 107. Rogers TB, Pati S, Gaa S, Riley D, Khakoo AY, Patel S, Wardlow RD, Frederick CA, Hall G, He LP, Lederer WJ. Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes.J Mol Cell Cardiol. 2011; 50:346–356.CrossrefMedlineGoogle Scholar
    • 108. Hosoda T, Zheng H, Cabral-da-Silva M, et al. Human cardiac stem cell differentiation is regulated by a mircrine mechanism.Circulation. 2011; 123:1287–1296.LinkGoogle Scholar
    • 109. Boström P, Frisén J. New cells in old hearts.N Engl J Med. 2013; 368:1358–1360.CrossrefMedlineGoogle Scholar
    • 110. Zhang X, Wang X, Zhu H, Kranias EG, Tang Y, Peng T, Chang J, Fan GC. Hsp20 functions as a novel cardiokine in promoting angiogenesis via activation of VEGFR2.PLoS One. 2012; 7:e32765.CrossrefMedlineGoogle Scholar
    • 111. Gennebäck N, Hellman U, Malm L, Larsson G, Ronquist G, Waldenström A, Mörner M. Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes.J Extracell Vesicles. 2013 May 17[Epub ahead of print].CrossrefMedlineGoogle Scholar
    • 112. Kakkar R, Lee RT. Intramyocardial fibroblast myocyte communication.Circ Res. 2010; 106:47–57.LinkGoogle Scholar
    • 113. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, Pasterkamp G, de Kleijn DP. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium.Stem Cell Res. 2007; 1:129–137.CrossrefMedlineGoogle Scholar
    • 114. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, Salto-Tellez M, Timmers L, Lee CN, El Oakley RM, Pasterkamp G, de Kleijn DP, Lim SK. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury.Stem Cell Res. 2010; 4:214–222.CrossrefMedlineGoogle Scholar
    • 115. Vrijsen KR, Sluijter JP, Schuchardt MW, van Balkom BW, Noort WA, Chamuleau SA, Doevendans PA. Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells.J Cell Mol Med. 2010; 14:1064–1070.MedlineGoogle Scholar
    • 116. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, Marbán E. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice.Circ Res. 2010; 106:971–980.LinkGoogle Scholar
    • 117. Crisostomo PR, Abarbanell AM, Wang M, Lahm T, Wang Y, Meldrum DR. Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions.Am J Physiol Heart Circ Physiol. 2008; 295:H1726–H1735.CrossrefMedlineGoogle Scholar
    • 118. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement.FASEB J. 2006; 20:661–669.CrossrefMedlineGoogle Scholar
    • 119. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, Pasterkamp G, de Kleijn DP. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium.Stem Cell Res. 2007; 1:129–137.CrossrefMedlineGoogle Scholar
    • 120. Waldenström A, Haney M, Biber B, Kavianipour M, Moritz T, Strandén P, Wikström G, Ronquist G. Ischaemic preconditioning is related to decreasing levels of extracellular adenosine that may be metabolically useful in the at-risk myocardium: an experimental study in the pig.Acta Physiol (Oxf). 2010; 199:1–9.CrossrefMedlineGoogle Scholar
    • 121. Kitakatze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5’-nucleotidase activity during myocardial ischemia and reperfusion in canine myocardium.Circulation. 1993; 87:208–215.LinkGoogle Scholar
    • 122. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.Circulation. 1991; 84:350–356.LinkGoogle Scholar
    • 123. Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Aguor EN, Timmers L, van Rijen HV, Doevendans PA, Pasterkamp G, Lim SK, de Kleijn DP. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury.Stem Cell Res. 2013; 10:301–312.CrossrefMedlineGoogle Scholar
    • 124. Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential.Front Genet. 2012; 3:56.CrossrefMedlineGoogle Scholar
    • 125. Zhang HG, Liu C, Su K, Su K, Yu S, Zhang L, Zhang S, Wang J, Cao X, Grizzle W, Kimberly RP. A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death.J Immunol. 2006; 176:7385–7393.CrossrefMedlineGoogle Scholar
    • 126. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, Altevogt P. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion.J Cell Biochem. 2008; 103:1783–1797.CrossrefMedlineGoogle Scholar
    • 127. Claudia S, Carolin S, Walter N. Unconventional secretion of fibroblast growth factor 2 and galectin-1 does not require shedding of plasmamembrane-derived vesicles.FEBS Lett. 2008; 582:1362–1368.CrossrefMedlineGoogle Scholar
    • 128. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumour derived exosomes selectively impair lymphocyte responses to interleukin-2.Cancer Res. 2007; 67:7458–7466.CrossrefMedlineGoogle Scholar
    • 129. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.Circulation. 1986; 74:1124–1136.LinkGoogle Scholar
    • 130. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.Circulation. 1991; 84:350–356.LinkGoogle Scholar
    • 131. Sanada S, Kitakaze M, Asanuma H, Harada K, Ogita H, Node K, Takashima S, Sakata Y, Asakura M, Shinozaki Y, Mori H, Kuzuya T, Hori M. Role of mitochondrial and sarcolemmal K(ATP) channels in ischemic preconditioning of the canine heart.Am J Physiol Heart Circ Physiol. 2001; 280:H256–H263.CrossrefMedlineGoogle Scholar
    • 132. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion–a target for cardioprotection.Cardiovasc Res. 2004; 61:372–385.CrossrefMedlineGoogle Scholar
    • 133. Bolli R. The late phase of preconditioning.Circ Res. 2000; 87:972–983.LinkGoogle Scholar
    • 134. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2.Nat Med. 2007; 13:486–491.CrossrefMedlineGoogle Scholar
    • 135. Yin C, Salloum FN, Kukreja RC. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70.Circ Res. 2009; 104:572–575.LinkGoogle Scholar
    • 136. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury.Cardiovasc Res. 2010; 87:535–544.CrossrefMedlineGoogle Scholar
    • 137. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z, Yang B. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes.J Cell Sci. 2007; 120:3045–3052.CrossrefMedlineGoogle Scholar
    • 138. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, Li YR, Li PF. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1.Nat Med. 2011; 17:71–78.CrossrefMedlineGoogle Scholar
    • 139. Raiborg C, Rusten TE, Stenmark H. Protein sorting into multivesicular endosomes.Curr Opin Cell Biol. 2003; 15:446–455.CrossrefMedlineGoogle Scholar
    • 140. Tavoosidana G, Ronquist G, Darmanis S, Yan J, Carlsson L, Wu D, Conze T, Ek P, Semjonow A, Eltze E, Larsson A, Landegren UD, Kamali-Moghaddam M. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer.Proc Natl Acad Sci U S A. 2011; 108:8809–8814.CrossrefMedlineGoogle Scholar

    eLetters(0)

    eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

    Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.